High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience
Abstract
High dose intermittent ARA-C (2
×
3
g/m2 i.v., days 1, 3, 5)
=
HiDAC was introduced as consolidation in AML by the CALGB-group in 1994. We treated 44 de novo AML patients in CR with up to four cycles of HiDAC (four cycles: 56.8%; three cycles: 22.7%; two cycles: 6.8%; one cycle: 13.7%). Median duration of aplasia (ANC
<
0.5
×
109/l) was 12 days. Neutropenic fever occurred in 38.6% of the patients during the first, 52.6% during the second, 45.7% during the third, and in 40% during the fourth cycle. Non-hematologic toxicity was tolerable. The median overall- and disease-free survival were 19.3 and 11.3 months, respectively. The best outcome was seen in patients aged <40 years. These results confirm that HiDAC is a safe and effective consolidation in AML.
Keywords: AML, Consolidation chemotherapy, High dose ARA-C, Toxicity
To access this article, please choose from the options below
PII: S0145-2126(04)00381-9
doi:10.1016/j.leukres.2004.10.009
© 2004 Elsevier Ltd. All rights reserved.
